Calicheamicin Derivatives for Antibody Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for further development of calicheamicin derivatives with alternative chemical and physical properties, as well as different biological activity profiles, to enhance their efficacy as payloads in antibody-drug conjugates (ADCs) for cancer treatment.
Innovation Solution
The development of novel calicheamicin derivatives, specifically compounds of Formula (I) and their use in antibody-drug conjugates, which include various substitutions and linkers to optimize payload release and biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If calicheamicin derivatives are developed with alternative chemical and physical properties, then the therapeutic efficacy of ADCs is improved, but the complexity of drug development and characterization increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of calicheamicin derivatives through various substitutions at defined positions (R1-R6, X, Y, Z groups). These structural parameter changes create derivatives with alternative chemical and physical properties while maintaining the core calicheamicin scaffold, thereby improving therapeutic efficacy without completely redesigning the molecule
Solution Approach 2:
The patent applies local quality by introducing specific substitutions at particular positions on the calicheamicin molecule (such as R1 at C-2, R2 at C-4, R3 at C-6, and substitutions on the disaccharide moiety). Each local substitution can independently modify properties like solubility, stability, or immunogenicity, allowing targeted optimization of specific characteristics while preserving the overall molecular framework
2Reliability
If novel calicheamicin derivatives with different biological activity profiles are created, then the effectiveness of cancer treatment is enhanced, but the difficulty of optimizing payload release profiles increases
Solution Approach 1:
The patent applies preliminary action by pre-installing various substituent groups (R1-R6, X, Y, Z) on the calicheamicin derivatives before conjugation to the antibody. These pre-installed groups are designed to influence payload release characteristics, allowing optimization of release profiles to occur during the drug design phase rather than requiring complex post-conjugation modifications
Solution Approach 2:
The patent applies the intermediary principle by using the disaccharide moiety and its substituents (particularly the Y and Z groups at positions C-10 and C-11) as mediating structures that can facilitate payload release. These intermediary groups can be designed to interact with specific cellular components or enzymatic systems, enabling controlled release without requiring complex release mechanisms
Data Source
AI summary
The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.